Drug intelligence / Profile preview

ARR-421

Development stage: Preclinical
Lead developer: ArriVent BioPharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ARR-421 is an investigational antibody-drug conjugate (ADC) being developed by ArriVent BioPharma in collaboration with Alphamab Oncology for the treatment of solid tumors. The program was announced in June 2024 as part of a multi-target ADC collaboration that leverages Alphamab's proprietary site-specific glycan-conjugation technology and linker-payload platform. ArriVent holds exclusive worldwide rights to develop and commercialize ARR-421 outside of Greater China (mainland China, Hong Kong, Macau, and Taiwan). As of mid-2024, the specific biological target and the nature of the cytotoxic payload have not been publicly disclosed, and the drug is in the early discovery or preclinical stages of development.

Beyond the preview

Go deeper on ARR-421.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARR-421.

Explore the full profile